Results: SBTX

Search articles by EPIC code
EPIC SBTX
views

I am branded Mr Angry - Lemming Investor video interview with Stuart Ashman of Skinbiotherapeutics

Let us be clear. When I said that Staurt Ashman said that month on month sales doubled in both July and August I said so because the bearded loon said so in an email to me. For him to backtrack as he does in this interview and suggest that "Mr Angry" is a bit confused, therefore makes me a bit more er....angry. If you have an hour of your life to spare, enjoy.

EPIC SBTX
views

SkinBioTherapeutics – interim numbers & warning of slight delay largely irrelevant, the clear potential remains - Buy

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.

EPIC SBTX
views

SkinBioTherapeutics – OptiBiotix’s share sale, who does it think it’s kidding?

Having been falling from early this month, shares in SkinBioTherapeutics (SBTX) are currently further lower after it announced “OptiBiotix Health Plc has placed 3,636,363 ordinary shares in SkinBioTherapeutics with new and existing institutional investors at a price of 55 pence per share”. With SkinBioTherapeutics CEO Stuart Ashman though arguing “the company is going from strength to strength” and “it is important to attract new investors who are keen to come on board to support us in the next stage of the company's development, as a commercial entity”, why the further share price fall?

Page 1 of 5 (44 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments